2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$69.62+$0.63 (+0.91%)
Price as of Jun 23, 2026 5:39 PM EDT- $8.2BMarket Cap
- 30.66%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$69.62+$0.63 (+0.91%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 47.0M -95.37% | 1.0B +22.44% | 829.3M +25.62% | 660.1M +48.91% | |
Cost of Revenue | 228.8M +43.51% | 159.4M -17.13% | 192.4M +38.09% | 139.3M +71.11% | |
Gross Profit | -181.8M -121.24% | 855.9M +34.39% | 636.9M +22.29% | 520.8M +43.91% | |
Sales and Marketing Expense | 207.1M +34.18% | 154.3M +3.45% | 149.2M +3.94% | 143.5M +185.21% | |
Research and Development Expense | -81.5M +3.09% | -79.0M +3.52% | -76.4M +14.65% | -66.6M +86.72% | |
Depreciation and Amortization Expense | 76.7M +7.90% | 71.0M -3.69% | 73.8M +70.98% | 43.1M +1,339.71% | |
Total Operating Expenses | 927.6M +99.98% | 463.8M -5.66% | 491.7M +25.24% | 392.6M +134.51% | |
Operating Profit | 469.0M -14.95% | 551.5M +63.36% | 337.6M +26.18% | 267.5M -3.03% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | 0 N/A | 0 +100.00% | -18.8M +10.71% | -16.9M +125.18% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -18.8M +10.71% | -16.9M +125.18% | |
Total Nonoperating Income and Expense | 21.5M -9.60% | 23.8M +45.57% | 16.3M +1,459.94% | 1.0M -5.08% | |
Income before Taxes | 466.9M -16.20% | 557.1M +59.94% | 348.3M +39.94% | 248.9M +0.16% | |
Income Taxes | 150.0M +32.68% | 113.0M +69.39% | 66.7M +42.63% | 46.8M +130.34% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 316.9M -28.64% | 444.1M +57.71% | 281.6M +39.31% | 202.1M -49.81% | |
Net Income from Continuing Operations Applicable to Common | 466.9M -16.20% | 557.1M +59.94% | 348.3M +39.94% | 248.9M +0.16% | |
Basic EPS and Net Income | 2.64 -24.57% | 3.50 +64.32% | 2.13 +43.92% | 1.48 -48.25% | |
Diluted EPS and Net Income | 2.56 -25.36% | 3.43 +63.33% | 2.10 +45.83% | 1.44 -47.45% | |
Basic Weighted Average Shares | 119.8M -5.51% | 126.8M -3.87% | 131.9M -3.59% | 136.8M -2.70% | |
Diluted Weighted Average Shares | 123.9M -4.27% | 129.4M -3.56% | 134.2M -4.56% | 140.6M -4.22% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 133.8M +15.51% | 115.8M -2.13% | 118.4M -49.46% | 234.2M +97.27% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | 128.6M -79.33% | |
Cash and Cash Equivalents and Short-Term Investments | 133.8M +15.51% | 115.8M -2.13% | 118.4M -67.37% | 362.8M -51.03% | |
Total Current Assets | 825.2M -23.97% | 1.1B +45.41% | 746.4M +1.00% | 739.0M -20.22% | |
Accumulated Depreciation | 33.2M +30.40% | 25.4M +29.34% | 19.7M +33.24% | 14.8M +12.64% | |
Property and Plant and Equipment and Net | 82.1M +9.46% | 75.0M +0.12% | 74.9M -0.83% | 75.6M +759.34% | |
Total Long-Term Assets | 10.9M -37.16% | 17.4M +4.34% | 16.7M +11.30% | 15.0M +614.89% | |
Total Assets | 2.5B +22.38% | 2.1B +19.05% | 1.7B -5.88% | 1.8B +66.74% | |
Income Taxes Payable | 42.9M +38.49% | 31.0M +3,118.59% | 963,000 N/A | 0 N/A | |
Total Short-Term Debt | 0 N/A | 0 N/A | 0 -100.00% | 13.3M -85.09% | |
Total Current Liabilities | 177.1M +27.31% | 139.1M +23.65% | 112.5M -13.99% | 130.8M +11.65% | |
Total Long-Term Debt | 2.1B +42.29% | 1.5B +0.44% | 1.5B +0.43% | 1.5B +89.62% | |
Total Long-Term Liabilities | 113.9M +107.94% | 54.8M +45.17% | 37.7M +23.94% | 30.4M +5,494.30% | |
Total Liabilities | 2.5B +45.71% | 1.7B +3.04% | 1.6B +1,161.16% | 130.8M +11.65% | |
Retained Earnings | 54.8M -84.78% | 359.9M +297.43% | 90.5M -36.77% | 143.2M +343.10% | |
Total Stockholders Equity | 48.8M -86.58% | 363.8M +334.11% | 83.8M -50.64% | 169.8M -13.79% | |
Total Shares Outstanding | 117.8M -4.35% | 123.1M -2.87% | 126.8M -6.20% | 135.2M -1.70% | |
Cash Flow | |||||
Cash from Operating Activities | 651.6M +36.01% | 479.1M +23.29% | 388.6M +61.83% | 240.1M -19.81% | |
Capital Expenditures | 7.0M -34.84% | 10.7M -30.06% | 15.3M +217.96% | 4.8M +230.13% | |
Cash from Investing Activities | -545.8M +107.75% | -262.7M +171.10% | -96.9M -80.10% | -487.0M +19.87% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -85.2M -61.08% | -218.9M -46.36% | -408.0M -212.59% | 362.4M +365.38% | |
Financials Ratio | |||||
Gross Margin | -386.75% -558.79% | 84.30% +9.76% | 76.80% -2.65% | 78.90% -3.35% | |
Operating Margin | 997.89% +1,737.21% | 54.32% +33.43% | 40.71% +0.44% | 40.53% -34.88% | |
Return on Assets | 13.81% -40.96% | 23.39% +48.49% | 15.75% +14.81% | 13.72% -71.30% | |
Return on Equity | 153.59% -22.59% | 198.42% -10.65% | 222.07% +101.47% | 110.23% -52.37% | |
Revenue Growth | -95.37% -525.03% | 22.44% -12.43% | 25.62% -47.61% | 48.91% -25.52% | |
Current Ratio | 4.66 -40.28% | 7.80 +17.59% | 6.64 +17.43% | 5.65 -28.54% | |
Cash Ratio | 0.76 -9.27% | 0.83 -20.84% | 1.05 -41.24% | 1.79 +76.69% | |
Debt-to-Equity Ratio | 43.89 +960.54% | 4.14 -76.86% | 17.89 +101.68% | 8.87 +99.27% | |
Debt-to-Assets Ratio | 0.85 +16.28% | 0.73 -15.64% | 0.87 +5.76% | 0.82 +3.04% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow